Conference Coverage

QOL is poorer for young women after mastectomy than BCS


 

REPORTING FROM SABCS 2018

Study details

The women studied were participants in the prospective Young Women’s Breast Cancer Study (YWS) and had a mean age of 37 years at diagnosis. Most (86%) had stage 0-2 breast cancer. (Those with metastatic disease at diagnosis or a recurrence during follow-up were excluded.)

Overall, 52% of the women underwent bilateral mastectomy, 20% underwent unilateral mastectomy, and 28% underwent breast-conserving surgery, Dr. Dominici reported. Within the mastectomy group, most underwent implant-based reconstruction (69%) or flap reconstruction (12%), while some opted for no reconstruction (11%).

Multivariate analyses showed that, in addition to mastectomy, other significant predictors of poorer breast satisfaction were receipt of radiation therapy (beta, –7.5 points) and having a financially uncomfortable status as compared with a comfortable one (–5.4 points).

Additional significant predictors of poorer psychosocial well-being were receiving radiation (beta, –6.0 points), being financially uncomfortable (–7 points), and being overweight or obese (–4.2 points), and additional significant predictors of poorer sexual well-being were being financially uncomfortable (–6.8 points), being overweight or obese (–5.3 points), and having lymphedema a year after diagnosis (–3.8 points).

The only significant predictors of poorer physical health were financially uncomfortable status (beta, –4.8 points) and lymphedema (–6.4 points), whereas longer time since surgery (more than 5 years) predicted better physical health (+6.0 points), according to Dr. Dominici.

Age, race, marital status, work status, education level, disease stage, chemotherapy, and endocrine therapy did not significantly predict any of the outcomes studied.

“This was a one-time survey of women who were enrolled in an observational cohort study, and we know that preoperative quality of life likely drives surgical choices,” she commented, addressing the study’s limitations. “Our findings may have limited generalizability to a more diverse population in that the majority of our participants were white and of high socioeconomic status.”

Dr. Dominici disclosed that she had no conflicts of interest. The study was funded by the Agency for Healthcare Research and Quality, Susan G. Komen, the Breast Cancer Research Foundation, and The Pink Agenda.

SOURCE: Dominici LS et al. SABCS 2018, Abstract GS6-06,

Pages

Recommended Reading

Oxybutynin nets dramatic reduction in hot flashes
MDedge Hematology and Oncology
Exercise during adjuvant breast cancer therapy improves CV outcomes
MDedge Hematology and Oncology
DTCs in marrow herald worse outcomes for early breast cancer
MDedge Hematology and Oncology
Dr. Ingrid A. Mayer on neoadjuvant endocrine therapy: The times are changing
MDedge Hematology and Oncology
AMAROS: Radiation has edge for axillary treatment
MDedge Hematology and Oncology
CTC counts signal treatment choice in ER-positive/HER2-negative metastatic breast cancer
MDedge Hematology and Oncology
Partial- and whole-breast irradiation very close in efficacy
MDedge Hematology and Oncology
Oxybutynin rapidly quells hot flashes
MDedge Hematology and Oncology
Extended AI therapy reduces breast cancer recurrence risk, ups fracture risk
MDedge Hematology and Oncology
Data underscore the importance of lifestyle interventions in breast cancer patients
MDedge Hematology and Oncology